ArticleJCO global oncology2020
Predictors of Survival After Head and Neck Squamous Cell Carcinoma in South America: The InterCHANGE Study.
Article in JCO global oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Risk factors for second primary esophageal cancer after head and neck squamous cell carcinoma: a systematic review and meta-analysis.ESMO gastrointestinal oncology · 2026Review
- Article
- Evaluating the Serum Levels of CD73 in Patients with Head and Neck Squamous Cell Carcinoma.Journal of dentistry (Shiraz, Iran) · 2026Article
- An Analysis of the Timeline to Diagnosis and Treatment in Oral Cavity and Oropharynx Cancer.Oral diseases · 2026Article
- Radiomic-Based Machine Learning Classifiers for HPV Status Prediction in Oropharyngeal Cancer: A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2025Review
- Advanced Stage Head and Neck Cancer Diagnosis: HEADSpAcE Consortium Health Systems Benchmarking Survey.Head & neck · 2025Article
- Differences in Oral Squamous Cell Carcinoma From Colombia and Spain: A Retrospective Cohort Study.Oral diseases · 2025Article
- Overall and disease-free survival in patients with HPV-positive and HPV-negative oropharyngeal cancer.Einstein (Sao Paulo, Brazil) · 2025Article
- Treatment regimens and survival among patients with head and neck squamous cell carcinoma from Mizo tribal population in northeast India - a single centre, retrospective cohort study.The Lancet regional health. Southeast Asia · 2024Article
- The Mutographs biorepository: A unique genomic resource to study cancer around the world.Cell genomics · 2024Review
- Article
- Potential Roles of Activin in Head and Neck Squamous Cell Carcinoma Progression and Mortality.Anticancer research · 2023Article
- Mutant HRas Signaling and Rationale for Use of Farnesyltransferase Inhibitors in Head and Neck Squamous Cell Carcinoma.Targeted oncology · 2023Review
- Article
- Factors related to the waiting time for scheduling an oral biopsy in Brazil: a multilevel analysis.BMC health services research · 2023Observational
- Prevalence of locoregional recurrence and survival post-treatment of head and neck cancers in Africa: a systematic review and meta-analysis.EClinicalMedicine · 2023Article
- Speech and Swallowing Rehabilitation Potentially Decreases Body Weight Loss and Improves Survival in Head and Neck Cancer Survivors.Dysphagia · 2023Observational
- The Brazilian National Oral Health Policy and oral cancer mortality trends: An autoregressive integrated moving average (ARIMA) model.PloS one · 2023Article
- Hospitalizations for oral and oropharyngeal cancer in Brazil by the SUS: impacts of the covid-19 pandemic.Revista de saude publica · 2023Article
- Risk prediction models for head and neck cancer: A rapid review.Laryngoscope investigative otolaryngology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
Abstract
purposeHead and neck squamous cell carcinoma (HNSCC) incidence is high in South America, where recent data on survival are sparse. We investigated the main predictors of HNSCC survival in Brazil, Argentina, Uruguay, and Colombia.
methodsSociodemographic and lifestyle information was obtained from standardized interviews, and clinicopathologic data were extracted from medical records and pathologic reports. The Kaplan-Meier method and Cox regression were used for statistical analyses.
resultsOf 1,463 patients, 378 had a larynx cancer (LC), 78 hypopharynx cancer (HC), 599 oral cavity cancer (OC), and 408 oropharynx cancer (OPC). Most patients (55.5%) were diagnosed with stage IV disease, ranging from 47.6% for LC to 70.8% for OPC. Three-year survival rates were 56.0% for LC, 54.7% for OC, 48.0% for OPC, and 37.8% for HC. In multivariable models, patients with stage IV disease had approximately 7.6 (LC/HC), 11.7 (OC), and 3.5 (OPC) times higher mortality than patients with stage I disease. Current and former drinkers with LC or HC had approximately 2 times higher mortality than never-drinkers. In addition, older age at diagnosis was independently associated with worse survival for all sites. In a subset analysis of 198 patients with OPC with available human papillomavirus (HPV) type 16 data, those with HPV-unrelated OPC had a significantly worse 3-year survival compared with those with HPV-related OPC (44.6%
conclusionLate stage at diagnosis was the strongest predictor of lower HNSCC survival. Early cancer detection and reduction of harmful alcohol use are fundamental to decrease the high burden of HNSCC in South America.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.